OBJECTIVES: BMT is an important technology used in the treatment of cancer patients. Cost estimates for this procedure vary, and mostly derive from estimates developed early in the dissemination of the technology. Our objective was to describe the costs associated with BMT. METHODS: Using 1999 MarketScan data, we analyzed commercial non-Medicare inpatient claims for patients who underwent initial BMT. Costs are comprised of total gross payments to all providers associated with the admission, including physicians and hospital facilities. RESULTS: 69 patients were eligible for analysis. 42% and 29% of the sample were from the North Central or Southern region of the U.S. Mean age was 44 years. The mean and median total claims paid for BMT were $83,027 and $76,826, respectively (95% CI: $72,520, $93,534). The average length of stay (LOS) was 25.6 days (95% CI: 22.9, 28.4). Average costs increased as LOS increased ($49,501 for LOS 0-15, $74,384 for LOS 16-30, $99,050 for LOS 31-45, and $169,431 for LOS > 45). The most frequent diagnoses for the sample were: multiple myeloma 19%, non-Hodgkin's lymphoma 16%, other types of cancer 13%, myeloma 10%, and chronic myeloid leukemia 9%. The average cost of BMT was significantly more expensive for patients with a diagnosis of leukemia (e.g. chronic myeloid leukemia) ($94,473) versus patients with other types of cancer ($72,535) (95% CI for the difference: $1,639, $42,498). Mean costs were higher for patients who died ($111,025) versus those patients discharged to their home, either under self-care ($80,618) or medical supervision ($65,291). CONCLUSIONS: We found that costs for BMT vary by diagnosis, LOS, and patient outcomes. Our estimate for BMT appears to be less expensive than initial estimates ($250,000). However, our analysis only included costs for initial BMT whereas other cost estimates include additional costs, such as costs for rehospitalizations, follow-up care and outpatient medications.
Prophylactic granulocyte-colony stimulating factor (G-CSF) reduces the incidence and duration of chemotherapy-induced neutropenia (CIN), thereby reducing the risk of complications, dose delays, and reductions that may compromise outcomes. A published risk threshold model for the cost-effective use of prophylactic G-CSF used direct costs derived from randomized clinical trials. With direct cost estimates of $1,000 per day, prophylactic G-CSF becomes cost-effective when the risk of hospitalization exceeds 40%, and this value is reflected in current ASCO guidelines for CSF use (Lyman et al, JNCI, 1993) . An updated analysis incorporating total institutional costs of $1750 per day reduces the risk threshold to 23% (Lyman et al, Eur J Cancer, 1998) . OBJECTIVE: Utilizing indirect cost estimates for neutropenia obtained from a pilot study (Calhoun at al, The Oncologist, 2001) , the risk threshold model was modified to incorporate indirect costs. METHODS: For parameters describing patients not receiving G-CSF, the indirect costs were fully added to the direct institutional costs. For the parameters describing patients receiving prophylactic G-CSF, the indirect costs were adjusted by the reduced incidence of severe neutropenia (50%), and further by the reduced probability of the development of febrile neutropenia (50%) related to G-CSF use. The new model was evaluated for indirect cost estimates ranging from $1,000 through $5,000 per episode. Patient out-of-pocket and indirect costs for an episode of severe neutropenia were estimated at $5,176 per episode, excluding hospitalizations (Calhoun at al, The Oncologist, 2001) . RESULTS: The addition of indirect costs yields a reduced threshold for prophylactic G-CSF use from 23% (no indirect costs) to 8% ($5,000 indirect costs). CONCLUSION: The incorporation of indirect costs into economic models provides a more complete assessment of the impact of prophylactic G-CSF from a societal perspective. Additional study of the model assumptions and indirect cost estimates are needed to further improve the decision model.
